PALO ALTO, Calif.–(BUSINESS WIRE)–Medable Inc. today announced $91 million in new funding to accelerate the life sciences industry’s shift to digital and decentralized clinical trials. The Series C funding round was led by Sapphire Ventures, with follow-on investment from existing investors GSR Ventures, PPD, Inc. (Nasdaq:PPD) and Streamlined Ventures. The funding brings Medable’s total capital raised to more than $136 million. For more, click here.